SP Scientific partners with i-Dositecno, integrates its fill-finish offering

By Vassia Barba

- Last updated on GMT

(Image: Getty/RGtimeline)
(Image: Getty/RGtimeline)

Related tags SP Scientific Injectables Sterile Injectables

SP Scientific partners with Spanish i-Dositecno to offer complete aseptic vial and syringe fill-finish lines to clients in Europe and North America.

Pennsylvania, US-based SP Scientific, a company providing freeze-drying and sterilizing services, announced a partnership with i-Dositecno, a developer of aseptic processing systems based in Barcelona, Spain.

Under the partnership, SP Scientific will include i-Dositecno’s vial and syringe filling equipment and capabilities in its offering to provide a full fill-finish line for clients in Europe and North America.

Through this collaboration, the companies aim to “serve the changing biopharmaceutical developers to their exact capacity requirements, as the market migrates to biological drugs,”​ Ian Whitehall, SP Scientific’s CMO, told us.

According to Whitehall, the partnership answers clients’ demands for one-stop fill-finish service, while i-Dositecno’s equipment ‘perfectly’ matches SP Scientific’s small-batch throughput freeze-drying for pharmaceutical injectable products.

As a result of the partnership, SP Scientific is expected to offer “the broadest lyophilization range available today”​ covering cycle development, stability, pilot, and clinical batch production through full aseptic manufacturing and commercial production batches, according to the company.

Furthermore, the development of this full processing line is expected to enable manufacturers to ensure the products’ integrity in the container that holds the medicine during transportation through a variety of global climates.

This is critical for biopharmaceuticals that need to be frozen and then thawed, freeze-dried, rehydrated, or encapsulated in liquid form without being touched by the atmosphere.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us

Products

View more

Webinars